XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Balance Sheets - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 2,669 $ 2,801
Accounts receivables, net of allowance for credit losses of $87 million and $91 million as of June 30, 2023 and December 31, 2022 3,539 3,696
Inventories 4,109 3,833
Prepaid expenses 1,228 1,162
Other current assets 486 549
Assets held for sale 56 10
Total current assets 12,088 12,051
Deferred income taxes 1,578 1,453
Other non-current assets 443 441
Property, plant and equipment, net 5,712 5,739
Operating lease right-of-use assets, net 418 419
Identifiable intangible assets, net 5,738 6,270
Goodwill [1] 17,118 17,633
Total assets 43,095 44,006
Current liabilities:    
Short-term debt 1,980 2,109
Sales reserves and allowances 3,433 3,750
Accounts payables 2,508 1,887
Employee-related obligations 451 566
Accrued expenses 2,498 2,151
Other current liabilities 973 1,005
Total current liabilities 11,843 11,469
Long-term liabilities:    
Deferred income taxes 534 548
Other taxes and long-term liabilities 3,973 3,847
Senior notes and loans 18,698 19,103
Operating lease liabilities 338 349
Total long-term liabilities 23,543 23,846
Commitments and contingencies, see note 10
Total liabilities 35,387 35,315
Teva shareholders' equity:    
Ordinary shares of NIS 0.10 par value per share; June 30, 2023 and December 31, 2022: authorized 2,495 million shares; issued 1,227 million shares and 1,217 million shares, respectively. 57 57
Additional paid-in capital 27,748 27,688
Accumulated deficit (13,950) (12,882)
Accumulated other comprehensive loss (2,677) (2,838)
Treasury shares as of June 30, 2023 and December 31, 2022: 106 million ordinary shares (4,128) (4,128)
Stockholders' equity attributable to Teva shareholders 7,052 7,897
Non-controlling interests 656 794
Total equity 7,708 8,691
Total liabilities and equity $ 43,095 $ 44,006
[1] Accumulated goodwill impairment as of June 30, 2023 and December 31, 2022 was approximately $27.6 billion.